Dirithromycin versus Amoxiclav in the treatment of acute exacerbations of chronic bronchitis

Journal of International Medical Research

Volumn 25, Issue 1, 1997, Pages 33-40

  Van Royen, P ^a   Betz, W ^b   Heyrman, J ^c   Taziaux, P ^d   Van Den Haute, M ^e   Poelman, M ^f  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Ctr Continued Educ Gen P   (Belgium)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f Eli Lilly Benelux   (Belgium)

Author keywords

Acute exacerbation of chronic bronchitis; Amoxiclav; Antibiotics; Chronic bronchitis; Dirithromycin; Macrolide

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMOXICLAV; ANTIBIOTIC AGENT; DIRITHROMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRONCHITIS; CANDIDIASIS; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREMOR; VERTIGO;

EID: 0031026354     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059702500105     Document Type: Article

References (18)

1. Barry AL, Pfaller MA, Fuchs PC: Dirithromycin disc susceptibility tests: interpretative criteria and quality control parameters. J Antimicrob Chemother 1993; 31 (Suppl C): 27-38.
2. Fernandes PB, Hardy DJ: Comparative in vitro potencies of 9 new macrolides. Drugs Exp Clin Res 1988; 14: 445-451.
3. Hardy DJ, Hensey DM, et al: Comparative in vitro activities of new 14-, 15-, 16-membered macrolides. AAC 1988; 32: 1710-1719.
4. Brogden R, Peters D: Dirithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 48: 599-616.
5. Mazzei T, Mini E, Novelli A, et al: Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993; 31 (Suppl C): 1-9.
6. Kirst HA, Sides GD: New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. AAC 1989; 33: 1419 -1422.
7. Sides GD, Cerimele BJ, Black HR, et al: Pharmacokinetics of dirithromycin. J Antimicrob Chemother 1993; 31 (Suppl C): 65-74.
8. Bergogne-Bérézin E: Tissue distribution of dirithromycin: comparison with erythromycin. J Antimicrob Chemother 1993; 31 (Suppl C): 77-88.
9. Cazzola M, Tufano MA, Polverino M, et al: Pulmonary penetration of dirithromycin in chronic bronchitis. In: 6th European Congress of Clinical Microbiology and Infectious Disease. Seville 1993: Abstract 320.
10. Rouveix B: Liaison des macrolides aux cytochromes P450 et interactions médicamenteuses: le cas de la dirithromycine. Lettre de l'Infectiologue, Numéro spécial, janvier 1994: 38.
11. Gaillat J: A multicenter study comparing the safety and efficacy of dirithromycin with erythromycin in the treatment of chronic bronchitis. J Antimicrob Chemother 1993; 31 (Suppl C): 139-154.
12. Sides GD: Clinical efficacy of dirithromycin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1993; 31 (Suppl C): 131-138.
13. Jacobson K: Clinical efficacy of dirithromycin in pneumonia. J Antimicrob Chemother 1993; 31 (Suppl C): 121-130.
14. Sides G, Conforti PM: Safety profile of dirithromycin. J Antimicrob Chemother 1993; 31 (Suppl C): 175-185.
15. Anthonisen NR, et al: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
16. Mechanic D: The concept of illness behaviour. J Chron Dis 1961; 15: 189-194.
17. Hosie J, Quinn P, Smits et al: A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 1995; 36: 173 -183.
18. Leroyer C, Boussac J, Lode H, et al: A comparison of 5 days of dirithromycin and 7 days of roxithromycin in acute bacterial exacerbation of chronic bronchitis. Immunol and Infect Diseases 1995; 5: 149-155.